Tuesday November 20, 8:00 am ET
DALLAS - HemoBioTech, Inc.’s (OTCBB: HMBT, http://www.hemobiotech.com),
HemoTech, potentially the first viable substitute for human blood, was highlighted in the
November 13, 2007 online edition of Scientific American as the lead story in its news
section.
The full text of the article, entitled “New Blood Substitutes Promise Relief For Sagging
Blood Banks,” notes that HemoTech “not only suppresses hemoglobin’s inherent
toxicity, but also serves to improve blood flow and even spur the creation of new red
blood cells.” Other products using hemoglobin or perfluorocarbon compounds as blood
substitutes have shown toxicity problems in their clinical trials. The article’s placement is
especially timely, given that it comes shortly after HemoBioTech announced taking
critical steps necessary for initiating trials in India. The goal is for such trials to run in
parallel with trials in the United States. The Scientific American online article is available
by clicking here, www.sciam.com/article.cfm?id=blood-substitutes-hemoglobin-anemia.
“We are pleased that Scientific American online has taken note of HemoBioTech’s
progress with HemoTech and the benefits it could provide the world,” said Arthur
Bollon, PhD, Chairman and Chief Executive Officer of HemoBioTech. “The
extraordinary potential advantages discussed in the article are a result of the patented
chemical method used to create HemoTech. We remain focused on our goal of extending
the initial clinical trial of HemoTech in order to move us closer to one day being able to
satisfy a major need in the broad blood use market.”
About Scientific American
Scientific American is a popular-science magazine, published (first weekly and later
monthly) since August 28, 1845, making it the oldest continuously published magazine in
the United States. It brings articles about new and innovative research to the amateur and
lay audience. In March 1996 Scientific American launched its own website at
SciAm.com.
About HemoBioTech, Inc.
HemoBioTech is working on the development and commercialization of HemoTech, a
novel human blood substitute technology exclusively licensed from Texas Tech
University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is
chemically modified with adenosine triphosphate, adenosine, and glutathione. In addition
to carrying oxygen through the bloodstream, HemoTech also induces erythropoiesis (red
blood cell production). Based on preclinical studies and an initial foreign human clinical
study, the company believes that HemoTech, due to its novel chemical composition, may
significantly diminish or even eliminate the intrinsic toxicities that have plagued other
attempts at developing blood substitutes. HemoTech is currently undergoing additional
studies to confirm and possibly expand on these results. HemoTech is being developed to
help reduce or eliminate the danger resulting from acute blood loss in trauma, surgery,
and other conditions. Corporate headquarters are located at 5001 Spring Valley Road,
Suite 1040-West, Dallas, Texas 75244. For further information visit our website at
http://www.hemobiotech.com.
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be
considered “forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Such statements include declarations regarding the intent, belief, or
current expectations of HemoBioTech and its management and are valid only as of today,
and we disclaim any obligation to update this information. These statements are subject
to known and unknown risks and uncertainties that may cause actual future experience
and results to differ materially from the statements made. Factors that might cause such a
difference include, among others the successful pre-clinical development, the successful
completion of clinical trials, the FDA review process and other governmental regulation,
pharmaceutical collaborator interest and ability to successfully develop and
commercialize drug candidates, competition from other pharmaceutical companies,
product pricing and third party reimbursement, and other factors which are included in
HemoBioTech’s Annual Report on Form 10-KSB for the year ended December 31, 2006,
as amended, and HemoBioTech’s other reports filed with the Securities and Exchange
Commission.
Contact:
HemoBioTech, Inc.
Arthur P. Bollon, PhD, 972-455-8950
Chief Executive Officer
abollon@hemobiotech.com
www.hemobiotech.com
or
Investor Relations:
The Investor Relations Group, Inc.
Christine Berni/Joseph Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
or
Media: